Dengue antibody prevalence in Buenos Aires

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to determine the percentage of the population in the metropolitan area of Buenos Aires that has antibodies against dengue. Participants aged 18 and older will undergo a small blood draw to measure Immunoglobulin G antibodies using ELISA. The study will also characterize different dengue serotypes and assess infection by other flaviviruses. A stratified sampling design will be employed, selecting participants from various income quintiles to ensure a representative sample.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* - Age ≥18 at the time of signing the informed consent.
* - Resident of the Buenos Aires metropolitan area

Exclusion Criteria:

* To be ≤17 years old.
* Inability to give informed consent.

Where it's running

• Fundación GESICA
  Ciudad Autónoma de Buenos Aire, Buenos Aires, Argentina Recruiting

Study contacts

• Study coordinator: Cristian Biscayart, MD
• Email: cristianbiscayart@gmail.com
• Phone: 541145204002

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dengue virus challenge in healthy adults to study immune responses

  Researchers will infect healthy adults with a weakened dengue virus to see how their bodies respond and how past exposure affects the reaction.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07706686

• Gut leakage in dengue: is the intestinal barrier affected during infection?

  Researchers are studying whether dengue infection disrupts the gut barrier and if that contributes to severe disease in adults with dengue who are in hospital.

  Recruiting University of Oxford · Chittagong, Chattogram Division · NCT07602920

• CP-COV03 versus placebo for adults with dengue or dengue-like illness

  This trial tests whether taking CP-COV03 for seven days helps adults with dengue (or dengue-like illnesses) recover faster and lower their viral levels compared with a placebo.

  Recruiting at 2 sites Phase 2/3 Hyundai Bioscience Co., Ltd. · Hanoi and 1 other locations · NCT07576868

• Community spread of multiple infectious diseases in Cambodia from a One Health perspective

  This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.

  Recruiting Institut Pasteur du Cambodge · Phnom Penh, Phnom Penh · NCT07358910

• Immune responses in dengue and sepsis

  This project will collect blood from people hospitalized with dengue-like illness or sepsis and from healthy volunteers to see how their immune responses change over time.

  Recruiting at 4 sites Institut Pasteur du Cambodge · Kampong Speu and 3 other locations · NCT07040202

• Emetine for Dengue: seeing if a pill can help adults with dengue work better

  This study tests three groups—emetine 6 mg, emetine 12 mg, or a placebo—to see if a 7-day oral course can improve outcomes for adults with dengue.

  Recruiting Phase 2/3 Johns Hopkins University · Baltimore, Maryland and 1 other locations · NCT07016321

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.